...
首页> 外文期刊>Journal of cardiac failure >Chronic systolic heart failure, guideline-directed medical therapy, and systemic hypotension-less pressure but maybe more risk (does this clinical scenario need more discussion?).
【24h】

Chronic systolic heart failure, guideline-directed medical therapy, and systemic hypotension-less pressure but maybe more risk (does this clinical scenario need more discussion?).

机译:慢性收缩性心力衰竭,指导性药物治疗和全身性低血压无压力,但风险可能更大(这种临床情况需要更多讨论吗?)。

获取原文
获取原文并翻译 | 示例
           

摘要

Many clinical trials have demonstrated the survival benefit of medication regimens that modulate the neurohormonal activation that occurs with chronic heart failure (HF). These medications, however, also commonly lower systemic blood pressure (BP). Low arterial BP in patients with chronic HF has been shown to be an independent predictor of increased mortality. Given this apparent paradox in therapeutic goals (treat aggressively but keep BP from going too low), how low should we allow systemic BP to go as a result of our medication regimens before we compromise the proven benefits of such drug therapy? Or is the association between the BP-lowering effects of standard therapy and outcomes in HF even meaningful clinically? It is from this perspective that the merits, potential clinical implications, and the relevant published literature pertaining to this patient and practice management issue will be discussed.
机译:许多临床试验表明,用药方案可以调节慢性心力衰竭(HF)发生的神经激素激活,从而具有生存优势。但是,这些药物通常还可以降低全身血压(BP)。慢性HF患者的低动脉血压已被证明是死亡率增加的独立预测因子。鉴于治疗目标存在明显的悖论(积极治疗,但不要使BP降低过低),在我们折衷这种药物治疗已证实的益处之前,由于我们的药物治疗方案,我们应允许全身性BP降低多少?还是标准疗法的降血压效果与HF的转归之间的关联在临床上甚至有意义?从这个角度出发,将讨论有关该患者和实践管理问题的优点,潜在的临床意义以及相关的已发表文献。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号